We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration.
John brings demonstrated business leadership to his new role with a background comprising more than 20 years of experience in driving growth and profitability, across Fortune 50, Big 5, non-profit, and start-up companies. His prior roles include positions of increasing responsibility within such leading organizations as the American Red Cross, Clinton Health Access Initiative, and Kedrion Biopharma. Most recently, he was CFO of The Floating Hospital in New York, one of New York City’s oldest healthcare charities with over 150 years of service to the neediest New Yorkers.
“I feel privileged to be joining The Max Foundation team,” says John. “Having worked in several charitable organizations, I am familiar with the Max Foundation’s lifesaving mission of acting as a bridge between patients and treatment while focusing on those no one else is helping. I am honored to be a part of this deeply humanitarian effort and look forward to actively supporting and working towards fulfilling our near- and long-term goals.”
“We are at a pivotal period of growth and expansion at the Max Foundation, adds Pat Garcia-Gonzales, CEO of the Max Foundation. “With John’s richly diverse experience including enterprise transformation and creating value across international markets, he is well suited to lead us into this next phase of growth and evolution as we strategically expand our external partnerships and internal talent”.
We’re excited about the depth and caliber of John’s background and look forward to his contributions as we further extend the Max Foundation’s mission of ensuring safe, high-impact medicine for all patients around the globe.
Please join us in welcoming John Menapace to the Max Foundation and wishing him much success.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
We’re pleased to share that the New England Journal of Medicine has published our “Letter to the Editor” on treatment-free remission for chronic myeloid leukemia in low- and middle-income countries! It was written in collaboration with Dr. Jerry Radich from the Fred Hutchinson Cancer Research Center and partner physicians from Armenia, the Dominican Republic, El….
In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low and middle income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.
Earlier this month, The Max Foundation celebrated the delivery of 110 BCR-ABL molecular tests to Mercy Medical Center Cambodia. The delivery was the first of its kind for Max, made possible through our 2018 Diagnostics Solidarity Fund. Two more deliveries – one to Kyrgyzstan and one to Bolivia – are in process now, and we’re hopeful there will be many more to come.
